White Papers
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry?
In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for >90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%).
Trinity’s AI algorithm incorporates publicly…
Read Now
Webinars
White Paper & On-demand Webinar:
This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each on its commercial performance, therapeutic value and R&D investment.
2021 saw 40 unique drug and biologic approvals, of which ~33% (13/40) were Oncology, followed by…
Read Now
White Papers
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023).
This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior).
The needle is moving.
Complete the form below to access the full white paper
By submitting…
Read Now
White Papers
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Key Takeaways from the 2023 NRDL Update
Continued importance of the NRDL
Accelerated access for innovative drugs
Evolving NRDL policy and payer landscape
Complete the form below to access the full white paper
By submitting this form, creating…
Read Now
White Papers
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in HCP perception, HCP advocacy or closing critical care gaps that impact overall patient outcomes.
When developing Key Medical Objectives (KMOs) and impact measurement models for Field Medical Affairs, several factors must be considered: the organization’s size, structure, specific roles, therapeutic…
Read Now
White Papers
Experts at Trinity Life Sciences interact with the inner workings of pharma from many perspectives as they engage with teams across life sciences organizations.
A common observation is that teams are working in silos: often unaware of what other teams are doing, sometimes pulling in different directions and frequently experiencing frustrations.
Internally, siloed working can create delays, unnecessary budget burn and re-work. Externally, it can result in negative coverage decisions or market underperformance, which ultimately impacts the patient. In some…
Read Now
White Papers
To date, life sciences’ efforts towards driving equitable healthcare have centered around access to care, early identification and prevention. Meanwhile, less attention has been given to the impact of the racial and ethnic homogeneity in trial populations. Clinical trial diversity continues to be one of the greatest challenges pharmaceutical and biotech companies face in ensuring the delivery of medicines that are effective for all people. Diverse clinical trial populations are an integral step in achieving equitable healthcare treatment.
While we…
Read Now
White Papers
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they deploy it to better support their innovative medicines at launch and beyond.
Complete the form below to access the full white paper
By submitting this…
Read Now
White Papers
The biopharmaceutical industry is known for its promise of life-changing innovations, but many companies continue to advance the wrong therapies into the clinic, resulting in underperformance and wasted resources. This white paper explores the concentration of activity on well-trodden ground, and the lack of focus on true innovation. With increasing global pricing pressures and policy changes, it is more important than ever to be selective about the drugs that are advanced into the market. This white paper offers insights and…
Read Now
White Papers
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased implementation of cost-effectiveness policies and the emergence of the consequences of these pricing controls and cost-effectiveness measures, including the Inflation Reduction Act (IRA) and Germany’s…
Read Now
